All In Biotech

NDA 207999 · Intercept

Ocaliva

Obeticholic Acid · Oral

NovelAccelerated approvalPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Feb 24, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

May 27, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

40

9 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 27, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewSummary Review
2 products under this application
  • OCALIVA · OBETICHOLIC ACID 10MG · TABLET, ORAL · Discontinued · TE AB
  • OCALIVA · OBETICHOLIC ACID 5MG · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Obeticholic Acid" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ocaliva (Obeticholic Acid)

2024 spending

$185M

Beneficiaries

2,104

16,339 claims

Per beneficiary

$87,912

$310.80 per unit

View as table
YearSpending
2020$97,483,170
2021$116,167,277
2022$132,584,847
2023$163,801,289
2024$184,965,829

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 68 on PubMed

Sponsor: Intercept

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.